Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors
Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major…
COVID-19 ages arteries prematurely with women most affected
A major international study finds COVID-19 survivors, especially women, face signs of accelerated vascular aging, yet early evidence…